Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.
Noxopharm Limited has notified the market that 2.6 million NOXAH convertible notes have ceased following repayment or redemption without conversion, effective 2 January 2026. The cessation of these convertible debt securities indicates a reduction in the company’s outstanding convertible obligations, which may simplify its capital structure and marginally lessen potential future equity dilution for existing shareholders.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
More about Noxopharm Ltd.
Noxopharm Limited (ASX:NOX) is an Australia-listed biotechnology company. While this announcement does not describe its operations, Noxopharm is generally known for developing oncology-focused therapeutics and related pharmaceutical technologies for global healthcare markets.
Average Trading Volume: 65,930
Technical Sentiment Signal: Buy
Current Market Cap: A$28.93M
Find detailed analytics on NOX stock on TipRanks’ Stock Analysis page.